Clinical trial
A Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study in 60 to 80-Year-Old Adults to Assess the Safety and Immunogenicity of BARS13
NCT04681833 is registered in ClinicalTrials.gov with Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study in 60 to 80-Year-Old Adults to Assess the Safety and Immunogenicity of BARS13
- Lead sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 24, 2021
- Completion date
- April 2, 2024
- Enrollment
- 125 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.